Trial Profile
Use of monoclonal antibody Nimotuzumab and radio-chemotherapy in the treatment of patients with locally advanced head and neck cancer - PL013 N-CRT-CC
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2020
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- Acronyms PL013N-CRT-CC
- 08 Mar 2017 New trial record